

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in *FLT3*-mutated acute myeloid leukemia

Julia S. Lee,¹ Charlotte B. Wagner,¹ Stacy Prelewicz,¹ Heena P. Kurish,² Robert Walchack,² Danielle A. Cenin,² Seema Patel,² Mimi Lo,³ Danielle Schlafer,⁴ Belinda K. T. Li,⁴ R. Donald Harvey III,⁴ Bestis Wasef,⁵ Jian Ying⁶ and Tibor Kovacs⁷


¹Department of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; ²Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH; ³Department of Pharmaceutical Services, University of California San Francisco, San Francisco, CA; ⁴Department of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA; ⁵Department of Pharmacy, Oregon Health and Science University Hospital, Portland, OR; ⁶Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT and ⁷Division of Hematology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA

Correspondence:


J. LEE - julialee@stanfordhealthcare.org

<https://doi.org/10.3324/haematol.2022.281967>

Supplementary Figure S1. CONSORT diagram of patient disposition



Supplementary Figure S2. Kaplan-Meier curves of Event-Free Survival in overall population, stratified by age (A), and in *FLT3*-ITD population by *NPM1* mutation status^a (B)



^aTwo patients with *FLT3*-ITD mutation had unknown *NPM1* status. *FLT3*-TKD data are not shown due to small sample size (*FLT3*-TKD *NPM1* mutant N=12, *FLT3*-TKD/*NPM1* wildtype N=15, *FLT3*-TKD *NPM1* unknown N=5)